Información de la revista
Vol. 34. Núm. 4.Julio 2014
Páginas 425-544
Vol. 34. Núm. 4.Julio 2014
Páginas 425-544
Acceso a texto completo
La genisteína y la proteína de soja mejoran el estado antioxidante renal en el síndrome nefrótico experimental
Soy protein and genistein improves renal antioxidant status in experimental nephrotic syndrome
Visitas
20467
Mohammad H. Javanbakhta, Reza Sadriab, Mahmoud Djalalia, Hoda Derakhshaniana, Payam Hosseinzadeha, Mahnaz Zareia, Gholamreza Azizic, Reza Sedaghatd, Abbas Mirshafieyb
a Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics. Tehran University of Medical Sciences, Tehran, Iran,
b Department of Pathobiology, School of Public Health. Tehran University of Medical Sciences, Tehran, Iran,
c Alborz University of Medical Sciences, Imam Hassan Mojtaba Hospital, Karaj, Alborz, Iran,
d Department of Pathology, School of Medicine. Shahed University, Tehran, Iran,
Este artículo ha recibido
Información del artículo

Antecedentes y objetivos: El síndrome nefrótico es una enfermedad crónica especialmente común en la infancia y la adolescencia. Las especies reactivas del oxígeno (ERO) y los radicales libres desempeñan un papel importante en la patogénesis del síndrome nefrótico. El objetivo de este estudio es evaluar los efectos de la genisteína (principal isoflavona de la soja) y la proteína de soja en el estado antioxidante renal de ratas nefróticas. Métodos: Este estudio se llevó a cabo durante 8 semanas con 40 ratas Sprague-Dawley machos adultas, que fueron divididas en cuatro grupos de 10. Cada uno de los grupos de estudio incluía: 1 control, 2 con síndrome nefrótico, 3 con síndrome nefrótico más una dieta a base de proteína de soja y 4 con síndrome nefrótico más una dieta a base de proteína de soja más genisteína. Se midieron tanto los niveles de proteína como de creatinina en orina. Tras la homogenización del tejido renal, se calcularon mediante espectrofotometría la capacidad antioxidante total (CAT), la actividad de la enzima catalasa, la concentración de malondialdehidos (MDA) y las proteínas carboniladas. El examen patológico de los riñones se realizó con el microscopio óptico. Además, se evaluó la viabilidad celular con un ensayo de MTT de la línea celular de fibrosarcoma WEHI-164. También se evaluó la actividad de la enzima MMP2 con distintas concentraciones de genisteína. Resultados: La capacidad antioxidante total aumentó significativamente en las ratas que tenían una dieta de genisteína, al igual que la actividad de la catalasa en aquellas con una dieta de soja y genisteína. En cambio, los grupos carbonilo de las proteínas y los niveles de MDA fueron significativamente inferiores en los animales con una dieta de soja y de genisteína. El examen patológico reveló una mejora significativa en los grupos con dietas de soja y de genisteína. Asimismo, la genisteína disminuyó la proliferación de la línea celular de fibrosarcoma WEHI-164. Conclusión: Parece ser que la proteína de soja reduce los daños renales causados por el síndrome nefrótico. La adición de genisteína a la proteína de soja produce mejoras en el estado antioxidante del tejido renal. La genisteína disminuye la proliferación celular.

Palabras clave:
Soja
Palabras clave:
Síndrome nefrótico
Palabras clave:
Antioxidante
Palabras clave:
Rata
Palabras clave:
Genisteína

Background and objectives: Nephrotic syndrome is a chronic disease especially common in the childhood and adolescence. Reactive oxygen species (ROS) and free radicals have significant role in the pathogenesis of nephrotic syndrome. The aim of this study was to evaluate the effect of soy protein and genistein (main isoflavone of soybean) on renal antioxidant status of nephrotic rats. Methods: This study was done for 8 weeks on 40 adult male Sprague-Dawley rats divided into four groups of 10 rats each. Study groups included: 1-Control, 2-Nephrotic syndrome, 3-Nephrotic syndrome+soy protein diet and 4-Nephrotic syndrome+soy protein diet+genistein. Urine protein and urine creatinine were measured. After homogenization of kidney, total antioxidant capacities (TAC), activities of catalase enzyme, the concentration of malondialdehydes (MDA) and carbolynated proteins were determined spectrophotometrically. Pathological examination was done on kidneys with light microscope. Cell viability was evaluated with MTT assay on WEHI-164 fibro sarcoma cell line. The MMP2 enzyme activity was evaluated in different concentrations of genistein. Results: Total antioxidant capacity was significantly increased in soy genistein. Catalase activity was significantly increased in soy and soy genistein groups. Protein carbonyl and MDA were significantly lower in soy and soy genistein groups. The scores of pathological examination showed significant improvement in soy and soy genistein groups. Genistein decreased the proliferation of the WEHI-164 fibrosarcoma cell line. Conclusion: It seems that soy protein decreases kidney damages in nephrotic syndrome. Adding genistein to soy protein causes improvements in antioxidant status of kidney tissue. Genistein decreases proliferation of cell.

Keywords:
Soy
Keywords:
Nephrotic Syndrome
Keywords:
Antioxidant
Keywords:
Rat
Keywords:
Genistein
El Texto completo está disponible en PDF
Bibliografía
[1]
Bagga A, Mantan M. Nephrotic syndrome in children. Indian J Med Res 2005;122:13-28. [Pubmed]
[2]
Palmieri B, Sblendorio V. Oxidative stress detection: what for? Eur Rev Med Pharmacol Sci 2007;11:27-54. [Pubmed]
[3]
Ghodake S, Suryakar A, Ankush R, Katkam R, Shaikh K, Katta A. Role of free radicals and antioxidant status in childhood nephrotic syndrome. Indian J Nephrol 2011;21:37-40. [Pubmed]
[4]
Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987;1:441-45.
[5]
Ahmad Sm. Oxidative stress and antioxidant defenses in biology. New York; London: Chapman & Hall; 1995.
[6]
Lieberman MA, Marks A, Peet A. Marks' basic medical biochemistry. LWW; 2012.
[7]
Mathew JL, Kabi BC, Rath B. Anti-oxidant vitamins and steroid responsive nephrotic syndrome in Indian children. J Paediatr Child Health 2002;38:450-37. [Pubmed]
[8]
Razavi A, Nouri HR, Mehrabian F, Mirshafiey A. Treatment of experimental nephrotic syndrome with artesunate. Int J Toxicol 2007;26:373-80. [Pubmed]
[9]
Mirshafiey A, Rehm BHA, Sahmani AA, Naji A, Razavi A. M-2000, as a new anti-inflammatory molecule in treatment of experimental nephrosis. Immunopharmacol Immunotoxicol 2004;26:611-9. [Pubmed]
[10]
Pedraza-Chaverri J, Barrera D, Hernandez-Pando R, Medina-Campos ON, Cruz C, Murguia F, et al. Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. Life Sci 2004;74:987-99. [Pubmed]
[11]
Yousef MI, Kamel KI, Esmail AM, Baghdadi HH. Antioxidant activities and lipid lowering effects of isoflavone in male rabbits. Food Chem Toxicol 2004;42:1497-503. [Pubmed]
[12]
Martínez RM, Giménez I, Lou JM, Mayoral JA, Alda JO. Soy isoflavonoids exhibit in vitro biological activities of loop diuretics. Am J Clin Nutr 1998;68:1354S-1357S. [Pubmed]
[13]
Tovar AR, Murguia F, Cruz C, Hernández-Pando R, Aguilar-Salinas CA, Pedraza-Chaverri J, et al. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome. J Nutr 2002;132:2562-9. [Pubmed]
[14]
Polkowski K, Mazurek AP. Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 2000;57:135-55. [Pubmed]
[15]
Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997;127:838S-41S.
[16]
Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004;37:277-85. [Pubmed]
[17]
Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6. [Pubmed]
[18]
Richard M, Portal B, Meo J, Coudray C, Hadjian A, Favier A. Malondialdehyde kit evaluated for determining plasma and lipoprotein fractions that react with thiobarbituric acid. Clin Chem 1992;38:704-9. [Pubmed]
[19]
Castegna A, Drake J, Pocernich C, Butterfield DA. Protein carbonyl levels-an assessment of protein oxidation. Methods in Biological Oxidative Stress 2003;3:161-8.
[20]
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. [Pubmed]
[21]
Khorramizadeh MR, Aalizadeh N, Pezeshki M, Ghahary A, Zeraati H, Berahmeh A, et al. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate¿specific antigen parameters. Int J Urol 2005;12:637-43. [Pubmed]
[22]
Seibel J, Molzberger AF, Hertrampf T, Laudenbach-Leschowski U, Diel P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur J Nutr 2009;48:213-20. [Pubmed]
[23]
23 Velasquez MT, Bhathena SJ. Dietary phytoestrogens: a possible role in renal disease protection. Am J Kidney Dis 2001;37:1056-68. [Pubmed]
[24]
Dozor AJ. The role of oxidative stress in the pathogenesis and treatment of asthma. Ann N Y Acad Sci 2010;1203:133-7. [Pubmed]
[25]
Anderson JW. Beneficial effects of soy protein consumption for renal function. Asia Pac J Clin Nutr 2008;17 Suppl 1:324-8. [Pubmed]
[26]
Lian F, Li Y, Bhuiyan M, Sarkar FH. p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer 1999;33:125-31. [Pubmed]
[27]
Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008;269:226-42. [Pubmed]
[28]
Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC, et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470-8. [Pubmed]
[29]
Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4. [Pubmed]
[30]
Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-89. [Pubmed]
Idiomas
Nefrología
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?